SCHEMBL213484

SCHEMBL213484

C[C@@H](Cl)c1ccccc1F

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.40
CYP3A4 P08684 2/20 0.40
IDO1 P14902 2/20 0.39
TDO2 P48775 2/20 0.39
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD11B1 P28845 3/20 0.36
GABRA1 P14867 1/20 0.36
GABRB2 P47870 1/20 0.36
MAPKAPK2 P49137 1/20 0.36
GAA P10253 1/20 0.35
HIF1A Q16665 1/20 0.35
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL931945 1.00 ACHE (0.40) ACHECYP3A4IDO1TDO2CES2
SCHEMBL30057869 1.00 ACHE (0.40) ACHECYP3A4IDO1TDO2CES2
SCHEMBL2865478 0.81 GABRA1 (0.43) CYP3A4ALDH1A1CYP2C9GABRA1GABRB2
SCHEMBL11258009 0.79 IDO1 (0.42) ACHECYP3A4IDO1TDO2CES2
SCHEMBL84442 0.79 GABRA1 (0.50) ACHECYP3A4IDO1TDO2CES2
SCHEMBL3406218 0.79 IDO1 (0.42) ACHECYP3A4IDO1TDO2CES2
SCHEMBL31852251 0.79 GABRA1 (0.50) ACHECYP3A4IDO1TDO2CES2
SCHEMBL15903486 0.79 ACHE (0.43) ACHECYP3A4IDO1TDO2CES2
SCHEMBL4219819 0.77 IDO1 (0.41) ACHECYP3A4IDO1TDO2CES2
SCHEMBL15247585 0.76 MAPKAPK2 (0.44) ACHECYP3A4IDO1TDO2CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440992-B2 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors Acturum Life Science AB (SE) 2016-09-13 US disclosed
US-8088780-B2 5,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptors ASTRAZENECA AB (SE) 2012-01-03 US disclosed
US-7947693-B2 2R)-2-[(2-amino-5-{[(1S)-1-(2-fluorophenyl)ethyl]thio}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]pentan-1-ol; neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases su COPD, asthma ASTRAZENECA AB (SE) 2011-05-24 US disclosed
US-20110092519-A1 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS ASTRAZENECA AB (SE) 2011-04-21 US disclosed
CN-101193897-B Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives ASTRAZENECA AB 2010-12-01 CN disclosed
CN-101193898-B Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives ASTRAZENECA AB 2010-12-01 CN disclosed
EP-1869056-B1 NOVEL 5-SUBSTITUTED 7-AMINO-Ý1,3¨THIAZOLOÝ4,5-D¨PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2010-11-10 EP disclosed
US-20090124637-A1 Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 ASTRAZENECA AB (SE) 2009-05-14 US disclosed
US-20080214578-A1 Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 ACTURUM REAL ESTATE AB (SE) 2008-09-04 US disclosed
CN-101193898-A Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives ASTRAZENECA AB (SE) 2008-06-04 CN disclosed
CN-101193897-A Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives ASTRAZENECA AB (SE) 2008-06-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092519-A1 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS CX3CR1, CCR2, CXCR3 ACHE 424/4885CYP3A4 2174/4885IDO1 2440/4885
US-20080214578-A1 Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 CX3CR1, CCR2, CXCR3 ACHE 528/4885CYP3A4 1442/4885IDO1 2023/4885
US-20090124637-A1 Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 CX3CR1, CCR2, CCR5 ACHE 514/4885CYP3A4 828/4885IDO1 2741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.